RAD51 and glioblastoma: Similarly, the alkali comet analysis shows a significant accumulation of DNA damage in all NCS-treated shRAD51-GBM (RAD51-deficient) lines compared to NCS-treated shSCM-GBM control lines (p ≤ 0.05) (Figure 3E).